

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Meloxidolor 5 mg/ml solution for injection for dogs, cats, cattle and pigs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substances:

Meloxicam 5 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Ethanol	150 mg
Poloxamer 188	
Sodium chloride	
Glycine	
Sodium hydroxide	
Hydrochloric acid	
Glycofurol	
Meglumine	
Water for injections	

Clear yellow solution.

3. CLINICAL INFORMATION

3.1 Target species

Dogs, cats, cattle (calves) and pigs.

3.2 Indications for use for each target species

Dogs:

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age.

For the relief of post-operative pain following dehorning in calves.

Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For the relief of post-operative pain associated with minor soft tissue surgery such as castration.

3.3 Contraindications

- Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
- Do not use in dogs and cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
- Do not use in dogs and cats less than 6 weeks of age nor in cats of less than 2 kg.
- Do not use in cattle and pigs suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.
- For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.
- Do not use in pigs less than 2 days old.
- For contraindications in the case of pregnant or lactating animals, see also section 3.7.

3.4 Special warnings

Treatment of piglets with the veterinary medicinal product before castration reduces post-operative pain.

To obtain pain relief for cattle and pigs during surgery co-medication with an appropriate anaesthetic/sedative/analgesic is needed.

To obtain the best possible pain relieving effect for pigs post-surgery the veterinary medicinal product should be administered 30 minutes before surgical intervention.

Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces post-operative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. During anaesthesia, monitoring and fluid therapy should be considered as standard practice.

Any oral follow-up therapy using meloxicam or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should not be administered in cats, as appropriate dosage regimens for such follow-up treatments have not been established.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

The veterinary medicinal product should not be administered by pregnant women or women of child-bearing potential as Meloxicam may be harmful to the foetus and unborn child.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs and cats:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Appetite loss ^a , Lethargy ^a Vomiting ^a , Diarrhoea ^a , Blood in faeces ^{a,b} , Haemorrhagic diarrhoea ^a , Haematemesis ^a , Gastrointestinal ulceration ^a Elevated liver enzymes ^a Renal failure ^a Anaphylactoid reaction ^c
--	--

^a These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

^b Occult.

^c Should be treated symptomatically.

Cattle:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Injection site swelling ^a Anaphylactoid reaction ^b
--	---

^a Following subcutaneous injection: slight and transient.

^b May be serious (including fatal) and should be treated symptomatically.

Pigs:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactoid reaction ^a
--	-------------------------------------

^a May be serious (including fatal) and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Dogs and cats:

Do not use during pregnancy or lactation.

Cattle:

Can be used during pregnancy.

Pigs:

Can be used during pregnancy and lactation.

3.8 Interaction with other medicinal products and other forms of interaction

For dogs and cats:

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. The veterinary medicinal product must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic veterinary medicinal products should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

For cattle and pigs:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

3.9 Administration routes and dosage

Dogs:

Musculo-skeletal disorders:

Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight).

Oral suspensions of meloxicam for dogs may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection.

Reduction of post-operative pain (over a period of 24 hours):

Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight) before surgery, for example at the time of induction of anaesthesia.

Cats:

Reduction of post-operative pain:

Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.

Cattle:

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

Pigs:

Locomotor disorders:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/25 kg body weight). If required, a second administration of meloxicam can be given after 24 hours.

Reduction of post-operative pain:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.

To ensure a correct dosage, body weight should be determined as accurately as possible. The use of suitably calibrated measuring equipment is recommended.

Avoid introduction of contamination during use.

The stopper should not be punctured more than 20 times.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

In case of overdose symptomatic treatment should be initiated.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Cattle:

Meat and offal: 15 days.

Pigs:

Meat and offal: 5 days.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QM01AC06

4.2 Pharmacodynamics

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by E. coli endotoxin administration in calves and pigs.

4.3 Pharmacokinetics

Absorption:

Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 mcg/ml in dogs and 1.1 mcg/ml in cats were reached approximately 2.5 hours and 1.5 hours post administration, respectively.

After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmax values of 2.1 mcg/ml were reached after 7.7 hours in young cattle.

Following single intramuscular doses of 0.4 mg meloxicam/kg, a Cmax value of 1.1 to 1.5 mcg/ml was reached within 1 hour in pigs.

Distribution:

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs and cats. More than 97 % of meloxicam is bound to plasma proteins.

The volume of distribution is 0.3 l/kg in dogs and 0.09 l/kg in cats.

In cattle and pigs, the highest meloxicam concentrations are to be found in liver and kidney.

Comparatively low concentrations are detectable in skeletal muscle and fat.

Metabolism:

Meloxicam is predominantly found in plasma. For dogs, cats and cattle it is also a major biliary excretion product whereas urine contains only traces of the parent compound.

In cattle, meloxicam is also a major excretion product in milk. In pigs, bile and urine contain only traces of the parent compound.

Five major metabolites were detected all having been shown to be pharmacologically inactive.

Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. The main pathway of meloxicam biotransformation is oxidation.

Elimination:

In dogs and cats, Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine in dogs.

In cats, the detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 21 % of the recovered dose is eliminated in urine (2 % as unchanged meloxicam, 19 % as metabolites) and 79 % in the faeces (49 % as unchanged meloxicam, 30 % as metabolites).

Meloxicam is eliminated with a half-life of 26 hours after subcutaneous injection in young cattle. In pigs, after intramuscular administration, the mean plasma elimination half-life is approximately 2.5 hours. Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf-life after first opening the immediate packaging: 28 days

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

Colourless type I glass vials of 10 ml, 20 ml or 100 ml, closed with a rubber stopper and sealed with an aluminium cap.

Multi-packs of 5 x 20 ml and 10 x 20 ml.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V.

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/13/148/001

EU/2/13/148/002

EU/2/13/148/003

EU/2/13/148/008

EU/2/13/148/009

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 22/04/2013

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Meloxidolor 20 mg/ml solution for injection for cattle, pigs and horses

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substances:

Meloxicam 20 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Ethanol	150 mg
Poloxamer 188	
Macrogol 300	
Glycine	
Disodium edetate	
Sodium hydroxide	
Hydrochloric acid	
Meglumine	
Water for injections	

Clear yellow solution.

3. CLINICAL INFORMATION

3.1 Target species

Cattle, pigs and horses.

3.2 Indications for use for each target species

Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

Horses:

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

3.3 Contraindications

- Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
- Do not use in horses less than 6 weeks of age.
- Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.
- For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age
- For contraindications in the case of pregnant or lactating animals, see also section 3.7.

3.4 Special warnings

Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces post-operative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

3.5 Special precautions for use

Special precautions for safe use in the target species:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

The veterinary medicinal product should not be administered by pregnant women or women of child-bearing potential as Meloxicam may be harmful to the foetus and unborn child.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Cattle:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Injection site swelling ^a Anaphylactoid reaction ^b
---	---

^a Following subcutaneous injection: slight and transient.

^b May be serious (including fatal) and should be treated symptomatically.

Pig:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactoid reaction ^a
---	-------------------------------------

^a May be serious (including fatal) and should be treated symptomatically.

Horse:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Injection site swelling ^a Anaphylactoid reaction ^b
--	---

^a Transient and resolves without intervention.

^b May be serious (including fatal) and should be treated symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Cattle and pigs:

Can be used during pregnancy and lactation.

Horses:

Do not use during pregnancy or lactation.

3.8 Interaction with other medicinal products and other forms of interaction

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

3.9 Administration routes and dosage

Cattle:

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

Pigs:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

Horses:

Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3 ml/100 kg body weight).

To ensure a correct dosage, body weight should be determined as accurately as possible. The use of suitably calibrated measuring equipment is recommended.

Avoid introduction of contamination during use.

The stopper should not be punctured more than 20 times.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

In case of overdose symptomatic treatment should be initiated.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Cattle:

Meat and offal: 15 days.

Milk: 5 days.

Pigs:

Meat and offal: 5 days.

Horses:

Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QM01AC06

4.2 Pharmacodynamics

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by E. coli endotoxin administration in calves, lactating cows and pigs.

4.3 Pharmacokinetics

Absorption:

After a single subcutaneous dose of 0.5 mg meloxicam/kg, C_{max} values of 2.1 mcg/ml and 2.7 mcg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.

After two intramuscular doses of 0.4 mg meloxicam/kg, a C_{max} value of 1.9 mcg/ml was reached after 1 hour in pigs.

Distribution:

More than 98 % of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

Metabolism:

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine

contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. The metabolism in horses has not been investigated.

Elimination:

Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.

In pigs, after intramuscular administration the mean plasma elimination half-life is approximately 2.5 hours.

In horses, after intravenous injection meloxicam is eliminated with a terminal half-life of 8.5 hours. Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf-life after first opening the immediate packaging: 28 days

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

Colourless type I glass vial containing 50 ml or 100 ml, closed with a rubber stopper and sealed with an aluminium cap.

Multi-pack of 12 x 100 ml

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V.

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/13/148/004

EU/2/13/148/005

EU/2/13/148/010

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 22/04/2013

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Carton for the 10 ml, 20 ml and 100 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Meloxidolor 5 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam 5 mg/ml

3. PACKAGE SIZE

10 ml
20 ml
100 ml

4. TARGET SPECIES

Dogs, cats, cattle (calves) and pigs.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Dogs, Cattle: subcutaneous or intravenous injection
Cats: subcutaneous injection
Pigs: intramuscular injection

7. WITHDRAWAL PERIODS

Withdrawal periods:

Cattle: Meat and offal: 15 days.
Pigs: Meat and offal: 5 days.

8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, use within 28 days.
Use by...

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V.

14. MARKETING AUTHORISATION NUMBERS

EU/2/13/148/001

EU/2/13/148/002

EU/2/13/148/003

EU/2/13/148/008

EU/2/13/148/009

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

Label for 100 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Meloxidolor 5 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam 5 mg/ml

3. TARGET SPECIES

Dogs, cats, cattle (calves) and pigs.

4. ROUTES OF ADMINISTRATION

Dogs, Cattle:
subcutaneous or intravenous injection.

Cats:
subcutaneous injection.

Pigs:
intramuscular injection.

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

Withdrawal periods:

Cattle:
Meat and offal: 15 days.

Pigs:
Meat and offal: 5 days.

6. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, use within 28 days.
Use by...

7. SPECIAL STORAGE PRECAUTIONS

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V.

9. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Label for 10 ml and 20 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Meloxidolor

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Meloxicam 5 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within 28 days.

Use by...

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Carton for 50 ml and 100 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Meloxidolor 20 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam 20 mg/ml

3. PACKAGE SIZE

50 ml
100 ml

4. TARGET SPECIES

Cattle, pigs and horses.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Cattle:
subcutaneous or intravenous injection.

Pigs:
intramuscular injection.

Horses:
intravenous injection.

7. WITHDRAWAL PERIODS

Withdrawal periods:

Cattle:
Meat and offal: 15 days.
Milk: 5 days.

Pigs, horses:
Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, use within 28 days.
Use by...

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V.

14. MARKETING AUTHORISATION NUMBERS

EU/2/13/148/004
EU/2/13/148/005
EU/2/13/148/010

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

Label for 100 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Meloxidolor 20 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam 20 mg/ml

3. TARGET SPECIES

Cattle, pigs and horses.

4. ROUTES OF ADMINISTRATION

Cattle: subcutaneous or intravenous injection

Pigs: intramuscular injection

Horses: intravenous injection

5. WITHDRAWAL PERIODS

Withdrawal periods:

Cattle: Meat and offal: 15 days. Milk: 5 days.

Pigs, horses: Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

6. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within 28 days.

Use by...

7. SPECIAL STORAGE PRECAUTIONS

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V.

9. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Label for 50 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Meloxidolor

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Meloxicam 20 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within 28 days.

Use by...

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Meloxidolor 5 mg/ml solution for injection for dogs, cats, cattle and pigs

2. Composition

Each ml contains:

Active substances:

Meloxicam 5 mg

Excipients:

Ethanol 150 mg

Clear yellow solution.

3. Target species

Dogs, cats, cattle (calves) and pigs.

4. Indications for use

Dogs:

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age.

For the relief of post-operative pain following dehorning in calves.

Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For the relief of post-operative pain associated with minor soft tissue surgery such as castration.

5. Contraindications

- Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
- Do not use in dogs and cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
- Do not use in dog and cats less than 6 weeks of age nor in cats of less than 2 kg.
- Do not use in cattle and pigs suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.
- For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.
- Do not use in pigs less than 2 days old.

- For contraindications in the case of pregnant or lactating animals, see also Section: Special warnings.

6. Special warnings

Special warnings:

Treatment of piglets with the veterinary medicinal product before castration reduces post-operative pain. To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative is needed.

To obtain pain relief for cattle and pigs during surgery co-medication with an appropriate anaesthetic/sedative/analgesic is needed.

To obtain the best possible pain relieving effect post-surgery the veterinary medicinal product should be administered 30 minutes before surgical intervention.

Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces post-operative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure.

Special precautions for safe use in the target species:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as there may be a potential risk of renal toxicity.

During anaesthesia, monitoring and fluid therapy should be considered as standard practice.

Any oral follow-up therapy using meloxicam or other NSAIDs should not be administered in cats, as appropriate dosage regimens for such follow-up treatments have not been established.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

The veterinary medicinal product should not be administered by pregnant women or women of child-bearing potential as Meloxicam may be harmful to the foetus and unborn child.

Pregnancy and lactation:

Dogs and cats: Do not use during pregnancy or lactation.

Cattle: Can be used during pregnancy.

Pigs: Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

For dogs and cats:

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. The veterinary medicinal product must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed

for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

For cattle and pigs:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

Overdose:

In case of overdose symptomatic treatment should be initiated.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Dogs and cats:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Appetite loss ^a , Lethargy ^a Vomiting ^a , Diarrhoea ^a , Blood in faeces ^{a,b} , Haemorrhagic diarrhoea ^a , Haematemesis ^a (vomiting blood), Gastrointestinal ulceration ^a Elevated liver enzymes ^a Renal failure ^a Anaphylactoid reaction ^c (Severe allergic reaction)
--	---

^a These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

^b Occult.

^c Should be treated symptomatically.

Cattle:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Injection site swelling ^a Anaphylactoid reaction ^b (Severe allergic reaction)
--	--

^a Following subcutaneous injection: slight and transient.

^b May be serious (including fatal) and should be treated symptomatically.

Pigs:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactoid reaction ^a (Severe allergic reaction)
--	--

^a May be serious (including fatal) and should be treated symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report

any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Dosage for each species

Dogs:

Musculo-skeletal disorders:

Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight).

Oral suspensions of meloxicam for dogs may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection.

Reduction of post-operative pain (over a period of 24 hours):

Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight) before surgery, for example at the time of induction of anaesthesia.

Cats:

Reduction of post-operative pain:

Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.

Cattle:

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

Pigs:

Locomotor disorders:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/25 kg body weight). If required, a second administration of meloxicam can be given after 24 hours.

Reduction of post-operative pain:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.

9. Advice on correct administration

To ensure a correct dosage, body weight should be determined as accurately as possible. The use of suitably calibrated measuring equipment is recommended.

Avoid introduction of contamination during use.

The stopper should not be punctured more than 20 times.

10. Withdrawal periods

Cattle:

Meat and offal: 15 days.

Pigs:

Meat and offal: 5 days.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf-life after first opening the immediate packaging: 28 days.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/13/148/001
EU/2/13/148/002
EU/2/13/148/003
EU/2/13/148/008
EU/2/13/148/009

Colourless type I glass vial of 10 ml, 20 ml or 100 ml, closed with a rubber stopper and sealed with an aluminium cap.

Multi-packs of 5 x 20 ml and 10 x 20 ml.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse events:

Le Vet Beheer B.V.
Wilgenweg 7
3421 TV Oudewater
The Netherlands
+31 348 563 434

Manufacturer responsible for batch release:

Produlab Pharma B.V.

Forellenweg 16

4941 SJ Raamsdonksveer

The Netherlands

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Meloxidolor 20 mg/ml solution for injection for cattle, pigs and horses

2. Composition

Each ml contains:

Active substances:

Meloxicam 20 mg

Excipients:

Ethanol 150 mg

Clear yellow solution.

3. Target species

Cattle, pigs and horses.

4. Indications for use

Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

Horses:

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

5. Contraindications

- Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
- Do not use in horses less than 6 weeks of age.
- Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.
- For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.
- For contraindications in the case of pregnant or lactating animals, see also Section: Special warnings.

6. Special warnings

Special warnings:

Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces post-operative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Special precautions for safe use in the target species:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

The veterinary medicinal product should not be administered by pregnant women or women of child-bearing potential as Meloxicam may be harmful to the foetus and unborn child.

Pregnancy and lactation:

Cattle and pigs: Can be used during pregnancy and lactation.

Horses: Do not use during pregnancy or lactation.

Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

Overdose:

In case of overdose, symptomatic treatment should be initiated.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Cattle:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Injection site swelling ^a Anaphylactoid reaction ^b (Severe allergic reaction)
---	--

^a Following subcutaneous injection: slight and transient.

^b May be serious (including fatal) and should be treated symptomatically.

Pig:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactoid reaction ^a (Severe allergic reaction)
--	--

^a May be serious (including fatal) and should be treated symptomatically.

Horse:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Injection site swelling ^a Anaphylactoid reaction ^b (Severe allergic reaction)
--	--

^a Transient and resolves without intervention.

^b May be serious (including fatal) and should be treated symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Cattle:

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

Pigs:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

Horses:

Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3 ml/100 kg body weight).

Avoid introduction of contamination during use.

The stopper should not be punctured more than 20 times.

9. Advice on correct administration

To ensure a correct dosage, body weight should be determined as accurately as possible. The use of suitably calibrated measuring equipment is recommended.

Avoid introduction of contamination during use.

The stopper should not be punctured more than 20 times.

10. Withdrawal periods

Cattle:

Meat and offal: 15 days.

Milk: 5 days.

Pigs:

Meat and offal: 5 days.

Horses:

Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf-life after first opening the immediate packaging: 28 days.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/13/148/004

EU/2/13/148/005

EU/2/13/148/010

Colourless type I glass vials of 50 ml or 100 ml, closed with a rubber stopper and sealed with an aluminium cap.

Multi-pack of 12 x 100 ml

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse events:

Le Vet Beheer B.V.
Wilgenweg 7
3421 TV Oudewater
The Netherlands
+31 348 563 434

Manufacturer responsible for batch release:

Produlab Pharma B.V.
Forellenweg 16
4941 SJ Raamsdonksveer
The Netherlands